Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12
| Autor: | Hye Ryun Kim, Hyun Chang, Keun-Wook Lee, Myung-Ju Ahn, Seong Hoon Shin, Ho Jung An, Sung-Bae Kim, Sang Hoon Chun, Yun-Gyoo Lee, Ji Hyun Park, Kyoung Eun Lee, In Gyu Hwang, Keon Uk Park, Bhumsuk Keam |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Larynx Male Cancer Research Neutrophils medicine.medical_treatment Gastroenterology 0302 clinical medicine Sum of target lesions Lymphocytes Immune Checkpoint Inhibitors Aged 80 and over Hazard ratio Platinum refractory Middle Aged Prognosis Primary tumor Head and Neck Cancer Progression-Free Survival medicine.anatomical_structure Oncology 030220 oncology & carcinogenesis Original Article Female Adult medicine.medical_specialty Clinical Decision-Making Immune check point Head and neck neoplasms Risk Assessment 03 medical and health sciences Refractory Antigen Internal medicine medicine Humans Lymphocyte Count Aged Retrospective Studies Chemotherapy business.industry Squamous Cell Carcinoma of Head and Neck Patient Selection Odds ratio medicine.disease Head and neck squamous-cell carcinoma 030104 developmental biology Drug Resistance Neoplasm Neoplasm Recurrence Local business Biomarkers Follow-Up Studies |
| Zdroj: | Cancer Research and Treatment : Official Journal of Korean Cancer Association |
| ISSN: | 2005-9256 1598-2998 |
| Popis: | Purpose This study was conducted to determine the effectiveness of immune checkpoint inhibitors (ICIs) in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) after platinum-containing chemotherapy. We also identified clinical biomarkers which may be predictive of patient prognosis.Materials and Methods We analyzed 125 patients with R/M HNSCC who received ICIs, retrospectively. Overall response rate (ORR) was the primary study outcome. Overall survival (OS) and progression-free survival (PFS) were the secondary study outcomes.Results The patients received anti–programmed cell death protein-1 (PD-1) (n=73, 58%), anti–programmed death-ligand 1 (PD-L1) (n=24, 19%), or a combination of anti–PD-1/PD-L1 and anti–cytotoxic T-lymphocyte antigen 4 (n=28, 22%). The median age was 57 years (range, 37 to 87). The location of the primary tumor was in the oral cavity in 28% of the cases, followed by oropharynx (27%), hypopharynx (20%), and larynx (12%). The ORR was 15% (19/125). With 12.3 months of median follow-up, median PFS was 2.7 months. Median OS was 10.8 months. A neutrophil-to-lymphocyte ratio (NLR) > 4 was significantly associated with poor response to ICIs (odds ratio, 0.30; p=0.022). A sum of the target lesions > 40 mm (hazard ratio [HR], 1.53; p=0.046] and a NLR > 4 (HR, 1.75; p=0.009) were considered to be predictive markers of short PFS. A poor performance status (HR, 4.79; p < 0.001), a sum of target lesions > 40 mm (HR, 1.93; p=0.025), and an NLR > 4 (HR, 3.36; p < 0.001) were the significant predictors for poor survival.Conclusion ICIs exhibited favorable antitumor activity in R/M HNSCC. Clinically, our findings can be used to recognize patients benefit from receiving ICI. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|